Cancer cells inhibition by cationic carbon dots targeting the cellular nucleus.
1,2,4,5-benzenetetramine
Cancer therapy
Cationic carbon dots
DNA binding
Nucleus targeting
Journal
Journal of colloid and interface science
ISSN: 1095-7103
Titre abrégé: J Colloid Interface Sci
Pays: United States
ID NLM: 0043125
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
01
12
2022
revised:
31
12
2022
accepted:
18
01
2023
pmc-release:
01
05
2024
pubmed:
27
1
2023
medline:
22
2
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Nucleus targeting is tremendously important in cancer therapy. Cationic carbon dots (CCDs) are potential nanoparticles which might enter cells and penetrate nuclear membranes. Although some CCDs have been investigated in nucleus targeting and applied in nuclear imaging, the CCDs derived from drugs, that are able to target the nucleus, bind with DNA and inhibit the growth of cancer cells have not been reported. In this project, 1, 2, 4, 5-benzenetetramine (Y15, a focal adhesion kinase inhibitor) derived cationic carbon dots (Y15-CDs) were prepared via a hydrothermal approach utilizing Y15, folic acid and 1,2-ethylenediamine as precursors. Based on the structural, optical, and morphologic characterizations, Y15-CDs possess rich amine groups and nitrogen in structure, an excitation-dependent photoluminescence emission, and a small particle size of 2 to 4 nm. The DNA binding experiments conducted through agarose gel electrophoresis, UV-vis absorption, fluorescence emission, and circular dichroism spectroscopies, prove that Y15-CDs might bind with DNA via electrostatic interactions and partially intercalative binding modes. In addition, the cell imaging and cytotoxicity studies in human foreskin fibroblasts (HFF), prostate cancer (PC3) and osteosarcoma cells (U2OS) indicate the nucleus targeting and anticancer abilities of Y15-CDs. Most interestingly, Y15-CDs exhibit a higher cytotoxicity to cancer cells (PC3 and U2OS) than to normal cells (HFF), inferring that Y15-CDs might be potentially applied in cancer therapy.
Identifiants
pubmed: 36701865
pii: S0021-9797(23)00098-X
doi: 10.1016/j.jcis.2023.01.086
pmc: PMC9957951
mid: NIHMS1869363
pii:
doi:
Substances chimiques
Carbon
7440-44-0
DNA
9007-49-2
Fluorescent Dyes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-206Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL156958
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA250597
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Semin Cancer Biol. 2021 Feb;69:166-177
pubmed: 31715247
Ultramicroscopy. 2021 Nov;230:113393
pubmed: 34607224
J Am Chem Soc. 2021 Mar 17;143(10):4064-4073
pubmed: 33661615
J Photochem Photobiol B. 2013 Jul 5;124:1-19
pubmed: 23648795
ACS Omega. 2020 May 05;5(20):11248-11261
pubmed: 32478212
J Inorg Biochem. 2008 Sep;102(9):1798-811
pubmed: 18621421
ACS Appl Mater Interfaces. 2019 Sep 11;11(36):32647-32658
pubmed: 31381288
Spectrochim Acta A Mol Biomol Spectrosc. 2009 May;72(4):876-9
pubmed: 19162536
ACS Sens. 2020 Sep 25;5(9):2724-2741
pubmed: 32812427
Nanoscale. 2016 Mar 28;8(12):6801-9
pubmed: 26957191
ACS Cent Sci. 2020 Dec 23;6(12):2179-2195
pubmed: 33376780
ACS Appl Mater Interfaces. 2021 Jul 7;13(26):31038-31050
pubmed: 34167297
Nat Rev Mol Cell Biol. 2003 Oct;4(10):757-66
pubmed: 14570049
RSC Adv. 2020 Jun 25;10(41):24203-24214
pubmed: 35516214
Colloids Surf B Biointerfaces. 2019 Aug 1;180:449-456
pubmed: 31096139
Chem Commun (Camb). 2020 Mar 10;56(20):3019-3022
pubmed: 32048647
Sci Rep. 2019 Oct 3;9(1):14278
pubmed: 31582791
Cancer Sci. 2017 Jul;108(7):1347-1356
pubmed: 28406574
Langmuir. 2019 Jul 16;35(28):9115-9132
pubmed: 31267753
J Phys Chem Lett. 2020 Feb 20;11(4):1357-1363
pubmed: 32017568
Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jun 15;234:118268
pubmed: 32203688
Mikrochim Acta. 2021 May 10;188(6):183
pubmed: 33970343
Bioconjug Chem. 2020 Mar 18;31(3):646-655
pubmed: 31884783
J Pharm Biomed Anal. 2012 Nov;70:598-601
pubmed: 22742920
Anal Bioanal Chem. 2019 Feb;411(5):967-972
pubmed: 30604036
Cell Cycle. 2010 Mar 1;9(5):1005-15
pubmed: 20160475
Mikrochim Acta. 2018 Aug 20;185(9):424
pubmed: 30128831
Transl Oncol. 2016 Aug;9(4):263-73
pubmed: 27567948
Biomater Sci. 2019 Apr 23;7(5):1940-1948
pubmed: 30785129
Appl Catal B. 2019 Jul 5;248:157-166
pubmed: 32831482
Mol Cancer Res. 2014 Apr;12(4):514-26
pubmed: 24464916
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250
pubmed: 31186061
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Aug;94:134-42
pubmed: 22537938
Anal Chem. 2019 Jul 16;91(14):9259-9265
pubmed: 31204808
J Colloid Interface Sci. 2022 Jul;617:730-744
pubmed: 35316786
Cell Cycle. 2009 Aug;8(15):2435-43
pubmed: 19571674